INmune Bio (NASDAQ:INMB – Get Free Report) is set to announce its earnings results after the market closes on Thursday, October 31st. Analysts expect the company to announce earnings of ($0.49) per share for the quarter.
INmune Bio (NASDAQ:INMB – Get Free Report) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.13. INmune Bio had a negative return on equity of 103.56% and a negative net margin of 26,333.59%. On average, analysts expect INmune Bio to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
INmune Bio Trading Up 4.4 %
Shares of INmune Bio stock opened at $5.22 on Friday. The stock has a 50-day moving average price of $5.74 and a 200 day moving average price of $7.98. The company has a market cap of $103.26 million, a P/E ratio of -2.72 and a beta of 1.85. INmune Bio has a 1 year low of $4.78 and a 1 year high of $14.74.
Insider Transactions at INmune Bio
Wall Street Analysts Forecast Growth
Several equities research analysts recently issued reports on the company. Raymond James assumed coverage on INmune Bio in a research note on Friday, September 27th. They issued an “outperform” rating and a $18.00 price objective for the company. Scotiabank assumed coverage on INmune Bio in a research note on Thursday, August 22nd. They issued a “sector outperform” rating and a $22.00 price objective for the company. Finally, Alliance Global Partners started coverage on INmune Bio in a research note on Monday. They issued a “buy” rating and a $20.00 price objective for the company.
View Our Latest Research Report on INMB
About INmune Bio
INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.
Read More
- Five stocks we like better than INmune Bio
- Retail Stocks Investing, Explained
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- 3 Monster Growth Stocks to Buy Now
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
- What is the Nikkei 225 index?
- The Downtrend in UPS Stock Isn’t Over Yet
Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter.